Lexington, United States
Concert Pharmaceuticals, Inc. is a biopharmaceutical company founded in 2006 and headquartered in the United States. The company's slogan, "Creating New Possibilities for Patients to Live Their Lives," reflects its commitment to developing innovative treatment options. Concert Pharmaceuticals is known for its DCE Platform® (deuterated chemical entity platform) which is utilized to discover small molecule drugs. By selectively incorporating deuterium into known molecules, the company aims to improve their pharmacokinetic or metabolic properties, thus enhancing clinical safety, tolerability, and efficacy.
The company's lead product candidate, currently in late-stage development, targets the treatment of alopecia areata, a serious autoimmune dermatological condition. In addition, Concert Pharmaceuticals is assessing a number of earlier-stage pipeline candidates. Notably, the company secured a significant $66.40M Post-IPO Equity investment on 01 June 2022, with RA Capital Management and BVF Partners as the investors.
Concert Pharmaceuticals' dedication to leveraging innovative scientific platforms and addressing critical unmet medical needs positions it as an attractive investment opportunity in the biotechnology and pharmaceutical industries.
